Creyon Bio
Founded 2019 · 22 employees on LinkedIn · 4 known investors
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease. It pairs this delivery technology with an AI/ML nucleic acid engineering platform (NucleIQ) to design nucleic acid therapies.
Investors · 4
Frequently asked questions
- What does Creyon Bio do?
- Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease. It pairs this delivery technology with an AI/ML nucleic acid engineering platform (NucleIQ) to design nucleic acid therapies.
- Who are Creyon Bio's investors?
- Creyon Bio's investors include BioBrit, DCVC (Data Collective), DCVC Bio, Tenmile.